TAFA chemokine like family member 1Genealiases: FAM19A1 · TAFA-1
Q-omics provides the consensus-scored TAFA1 profile across patient tissues and cancer cell-line models. TAFA1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TAFA1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TAFA1 RNA expression shows 14,709 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where TAFA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAFA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAFA1 survival associations across molecular data types. TAFA1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAFA1 RNA expression–survival associations across cancer types. High TAFA1 expression shows unfavorable associations in UVM, but favorable associations in HNSC, ACC, LGG, CESC and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TAFA1 RNA expression.
This table summarizes TAFA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TAFA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAFA1 shows lower tumor expression in KIRC, THCA, LUSC, BRCA, LUAD and KICH. The KIRC box plot shows higher TAFA1 RNA expression in normal versus tumor tissue (log2 FC = −0.277, t-test p < 0.001).
This table shows molecular features associated with TAFA1 in patient tissues and cancer cell lines. In patient samples, TAFA1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TAFA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
